TY - JOUR T1 - Acetylsalicylic Acid Resistance After Renal Transplantation JF - In Vivo JO - In Vivo SP - 141 LP - 144 VL - 29 IS - 1 AU - ADAM VARGA AU - BARBARA SANDOR AU - KAROLY KALMAR NAGY AU - MARIA VIOLA AU - ANDRAS TOTH AU - KATALIN GOMBOS AU - KALMAN TOTH AU - PETER SZAKALY Y1 - 2015/01/01 UR - http://iv.iiarjournals.org/content/29/1/141.abstract N2 - Background: Cardiovascular diseases are a leading cause of mortality after kidney transplantation. According to guidelines, acetylsalicylic acid (ASA) must be given as preventive antiplatelet therapy, but resistance to this drug is also well-known. Patients and Methods: A total of 214 renal transplant patients were included in our study and took 100 mg of ASA q.d. Aggregometry was performed to determine resistance. Twenty-four variables were examined using logistic regression analysis as possible causes of resistance. Results: ASA resistance was observed in 40.18% of the patients. Resistance reduced concomitant statin therapy and significantly increased simultaneous cyclosporine therapy. Conclusion: Our study assessed the post-transplant ASA resistance in a large population. Clarification of this matter is crutial, since one of the major preventive pharmacological therapies of cardiovascular mortality is not effective in a significant number of patients. ER -